Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.~* Adult males and non-pregnant, non-lactating females.~* Documented evidence of chronic HBV infection.~* Hepatitis e antigen (HBeAg)-negative, chronic hepatitis B with all of the following:~  * HBeAg-negative and hepatitis B e antibody (HBeAb) positive at screening.~ * Screening HBV DNA ≥ 2 x 10\^4 IU/mL.~ * Screening serum alanine aminotransferase (ALT) level \> 60 U/L (males) or \> 38 U/L (females) and ≤ 10 x the upper limit of the normal range (ULN).~* Treatment-naive participants (defined as \< 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue), OR treatment-experienced participants (defined as participants meeting all entry criteria \[including HBV DNA and serum ALT criteria\] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue).~* Previous treatment with interferon (pegylated or non pegylated) must have ended at least 6 months prior to Baseline.~* Adequate renal function.~* Normal electrocardiogram (ECG).~Key Exclusion Criteria:~* Females who are breastfeeding.~* Males and females of reproductive potential who are unwilling to use an effective, protocol-specified method(s) of contraception during the study.~* Co-infection with hepatitis C virus, human immunodeficiency virus (HIV), or hepatitis D virus.~* Evidence of hepatocellular carcinoma.~* Any history of, or current evidence of, clinical hepatic decompensation.~* Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) \> 10 x ULN~* Received solid organ or bone marrow transplant.~* History of malignancy within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible.~* Currently receiving therapy with immunomodulators (eg, corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion.~* Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients.~* Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance.~* Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAF 25 mg (Type: EXPERIMENTAL): TAF + TDF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
- TDF 300 mg (Type: ACTIVE_COMPARATOR): TDF + TAF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
- Open-label TAF (Type: EXPERIMENTAL): All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.~After the end of study treatment, participants can either switch to commercially available anti-HBV treatments in their country or will be followed every 4 weeks, for up to 24 weeks off treatment (treatment-free follow-up (TFFU)) for safety assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).